|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,175.00 JPY | +0.18% |
|
-0.09% | +3.92% |
| 06-30 | Trump's push for the world's lowest drug prices hits snag with mid-sized companies | RE |
| 06-26 | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| Market Cap | 3,896B 23.96B 20.98B 19.37B 18.08B 34B 2,268B 34.65B 231B 90.01B 1,119B 90.08B 88.05B | P/E 2027 * |
11.3x | P/E 2028 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 3,820B 23.49B 20.57B 18.98B 17.72B 33.33B 2,223B 33.97B 226B 88.24B 1,097B 88.3B 86.31B | EV / Sales 2027 * |
1.7x | EV / Sales 2028 * | 1.69x |
| Free-Float |
98.88% | Yield 2027 * |
3.7% | Yield 2028 * | 3.82% |
Last Transcript: Astellas Pharma Inc.
| 1 day | +0.18% | ||
| 1 week | -0.09% | ||
| Current month | -4.73% | ||
| 1 month | -4.73% | ||
| 3 months | -16.65% | ||
| 6 months | +3.57% | ||
| Current year | +3.92% |
| 1 week | 2,128 |  | 2,204 |
| 1 month | 2,041 | | 2,275 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,365 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.18% | -0.09% | +55.14% | +0.88% | 24.02B | |
| -2.48% | +8.83% | +54.68% | +158.23% | 1,097B | |
| -1.76% | +9.81% | +66.64% | +54.77% | 622B | |
| -1.05% | +9.40% | +38.03% | +88.88% | 449B | |
| +0.83% | +6.34% | +29.51% | +24.01% | 334B | |
| -1.38% | +6.09% | +37.91% | +25.49% | 294B | |
| +0.30% | +5.24% | +31.61% | +42.02% | 286B | |
| -0.10% | +4.88% | -28.09% | -41.02% | 213B | |
| +0.44% | +5.05% | +30.67% | +63.74% | 195B | |
| +0.01% | +1.18% | +14.16% | +66.21% | 157B | |
| Average | -0.50% | +6.08% | +33.02% | +48.32% | 367.08B | |
| Weighted average by Cap. | -1.16% | +8.66% | +41.43% | +78.77% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,249B 13.83B 12.11B 11.18B 10.44B 19.63B 1,309B 20B 133B 51.95B 646B 51.99B 50.82B | 2,079B 12.79B 11.2B 10.33B 9.65B 18.15B 1,210B 18.49B 123B 48.03B 597B 48.07B 46.99B |
| Net income | 346B 2.13B 1.86B 1.72B 1.6B 3.02B 201B 3.08B 20.46B 7.99B 99.33B 7.99B 7.81B | 327B 2.01B 1.76B 1.63B 1.52B 2.86B 190B 2.91B 19.36B 7.56B 94.01B 7.57B 7.4B |
| Net Debt | -76.78B -472M -413M -382M -356M -670M -44.69B -683M -4.54B -1.77B -22.05B -1.77B -1.74B | -391B -2.41B -2.11B -1.94B -1.82B -3.41B -228B -3.48B -23.15B -9.04B -112B -9.04B -8.84B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/06/26 | ¥2,175.00 | +0.18% | 9,968,900 |
| 29/06/26 | ¥2,171.00 | +1.21% | 10,716,900 |
| 26/06/26 | ¥2,145.00 | -0.09% | 6,216,800 |
| 25/06/26 | ¥2,147.00 | -0.58% | 4,672,000 |
| 24/06/26 | ¥2,159.50 | +1.24% | 5,998,200 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
